Pre-operative stereotactic radiosurgery and peri-operative dexamethasone for resectable brain metastases: a two-arm pilot study evaluating clinical outcomes and immunological correlates
Caroline S Jansen,Meghana S Pagadala,Maria A Cardenas,Roshan S Prabhu,Subir Goyal,Chengjing Zhou,Prasanthi Chappa,BaoHan T Vo,Chengyu Ye,Benjamin Hopkins,Jim Zhong,Adam Klie,Taylor Daniels,Maedot Admassu,India Green,Neil T Pfister,Stewart G Neill,Jeffrey M Switchenko,Nataliya Prokhnevska,Kimberly B Hoang,Mylin A Torres,Suzanna Logan,Jeffrey J Olson,Edjah K Nduom,Luke Del Balzo,Kirtesh Patel,Stuart H Burri,Anthony L Asher,Scott Wilkinson,Ross Lake,Aparna H Kesarwala,Kristin A Higgins,Pretesh Patel,Vishal Dhere,Adam G Sowalsky,Hannah Carter,Mohammad K Khan,Haydn Kissick,Zachary S Buchwald
DOI: https://doi.org/10.1038/s41467-024-53034-6
2024-10-14
Abstract:Enhancing the efficacy of immunotherapy in brain metastases (BrM) requires an improved understanding of the immune composition of BrM and how this is affected by radiation and dexamethasone. Our two-arm pilot study (NCT04895592) allocated 26 patients with BrM to either low (Arm A) or high (Arm B) dose peri-operative dexamethasone followed by pre-operative stereotactic radiosurgery (pSRS) and resection (n= 13 per arm). The primary endpoint, a safety analysis at 4 months, was met. The secondary clinical endpoints of overall survival, distant brain failure, leptomeningeal disease and local recurrence at 12-months were 66%, 37.3%, 6%, and 0% respectively and were not significantly different between arms (p= 0.7739, p= 0.3884, p= 0.3469). Immunological data from two large retrospective BrM datasets and confirmed by correlates from both arms of this pSRS prospective trial revealed that BrM CD8 T cells were composed of predominantly PD1+ TCF1+ stem-like and PD1+ TCF1-TIM3+ effector-like cells. Clustering of TCF1+ CD8 T cells with antigen presenting cells in immune niches was prognostic for local control, even without pSRS. Following pSRS, CD8 T cell and immune niche density were transiently reduced compared to untreated BrM, followed by a rebound 6+ days post pSRS with an increased frequency of TCF1- effector-like cells. In sum, pSRS is safe and therapeutically beneficial, and these data provide a framework for how pSRS may be leveraged to maximize intracranial CD8 T cell responses.